Tumor necrosis factor receptor superfamily member 5–CD40 ligand complex (CD40–CD40L) (CD40–CD40L)

The CD40–CD40 ligand (CD40L) complex is a fundamental costimulatory signaling unit that facilitates communication between the adaptive and innate immune systems. CD40, a member of the tumor necrosis factor receptor superfamily (TNFRSF5), is constitutively expressed on antigen-presenting cells such as B cells, dendritic cells, and macrophages, while its ligand, CD40L (CD154), is transiently expressed on activated T cells (UniProt P25942, P29965). The formation of this immune synapse interface is essential for B-cell proliferation, immunoglobulin isotype switching, and the development of high-affinity memory B cells within germinal centers (PubMed 28844077). Beyond B cells, the interaction licenses dendritic cells to effectively prime CD8+ T-cell responses, making it a pivotal regulator of cellular immunity. Dysregulation of the CD40–CD40L axis is a hallmark of various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, and plays a role in chronic inflammatory conditions like atherosclerosis. Consequently, therapeutic interventions focus on either blocking this interface to achieve immunosuppression in autoimmunity and transplantation or using agonistic agents to stimulate CD40 for enhanced anti-tumor activity in oncology (PubMed 31515284). While early clinical attempts were hindered by thromboembolic complications linked to CD40L expression on platelets, modern drug design has produced safer, next-generation biologics that specifically target this interface.

Other names

CD40–CD154 interactionCD40–TNFSF5 complexCD40–TNFRSF5 interactionCD40–CD40L axisCD40–CD40 ligand costimulatory pathway

Antagonistic molecules block the CD40–CD40L interaction to prevent T-cell-dependent B-cell activation and pro-inflammatory signaling, while agonistic molecules bind to CD40 to trigger downstream signaling pathways that activate antigen-presenting cells for anti-tumor immunity.